Results from the VOYAGER PAD Trial reported

A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes…

Novartis backs hydroxychloroquine trial in COVID-19 fight

Swiss pharmaceutical giant Novartis said Monday it would sponsor a clinical trial in the US using hydroxychloroquine to treat patients hospitalised with COVID-19. Novartis said it had reached an agreement with the US food and Drug Administration (FDA) to go ahead with a phase III clinical trial with around 440…